Sharecare names Quest Diagnostics its preferred laboratory partner to advance digital health management
Friday, July 12, 2019 12:00 AM

ATLANTA (July 12, 2019) – Sharecare, the digital health company that helps people manage all their health in one place, and Quest Diagnostics (NYSE: DGX) have formed a collaboration designed to improve digital health and disease management for a range of health care consumers.

Sharecare has named Quest its preferred laboratory partner for its comprehensive digital health platform. Sharecare and Quest Diagnostics also intend to jointly explore the development of disease management programs and other services to empower better health. In addition, Quest has made a strategic investment in Sharecare for an undisclosed sum with Goldman Sachs serving as Sharecare’s financial advisor. Additional terms were not disclosed.

“With its expertise, quality and reach, Quest Diagnostics is the trusted leader in diagnostic information services. Together, we will elevate the Sharecare experience and empower individuals to access better insights into their health risks,” said Jeff Arnold, co-founder, chairman and CEO for Sharecare.

Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection
Thursday, July 11, 2019 03:55 PM

Washington, D.C. (July 11, 2019) – BIO’s President and CEO Jim Greenwood issued the following statement after it was reported that the Trump administration is withdrawing its proposed rebate rule that would have required savings from drugmakers’ rebates be passed along to seniors enrolled in the Medicare drug benefit program: 

“The administration has abandoned one of the only policy solutions that would have truly lowered what patients are forced to pay out of pocket for the medicines they need. This decision discards a proposal that would have also delivered meaningful transparency to an opaque system that puts the financial interests of middlemen ahead of the well-being of patients.

“It is deeply disappointing the administration succumbed to the same old scare tactics we see from the insurance industry whenever policymakers aim to address the discriminatory tactics insurers use against patients. The president has promised to rein in the role of middlemen and ensure patients directly benefit from the significant rebates biopharmaceutical companies provide, but today that promise was broken. 

“This decision has dealt a blow to some of the most vulnerable patients, and it only heightens the urgency for Congress to adopt a reasonable cap on out-of-pocket costs for America’s seniors.”

Remarks by President Donald Trump, May 11, 2018:

  • “We’re also increasing competition and reducing regulatory burdens so drugs can be gotten to the market quicker and cheaper.  We’re very much eliminating the middlemen.  The middlemen became very, very rich.  Right? Whoever those middlemen were — and a lot of people never even figured it out — they’re rich.  They won’t be so rich anymore.”
  • “Our plan will end the dishonest double-dealing that allows the middleman to pocket rebates and discounts that should be passed on to consumers and patients.”


About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

New pharma boss: Next EU Commission should be clear on how to protect innovation
Friday, June 28, 2019 12:00 AM

The next EU Commission should take a stronger position on innovation in the pharma sector, the new leader of the European Federation of Pharmaceutical Industries and Associations (EFPIA) told in an interview.

“It will be important for the next European Commission to make an official statement on how they feel about innovation and how they want to protect and develop innovation,” Jean-Christophe Tellier, the newly elected President of EFPIA and CEO of biopharmaceutical company UCB, told EURACTIV.

He added that it is equally important to put in place frameworks to facilitate access to innovation. “We’ve noticed that EU countries are delaying the ability to put innovations on the market due a very long process of pricing, but the deadline of the patent is always the same,” he said.

BIO Applauds Enactment of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act
Tuesday, June 25, 2019 12:47 PM

Legislation will strengthen pipeline of medical countermeasures against serious public health threats

Washington, DC (June 25, 2019) – The Biotechnology Innovation Organization (BIO) today applauds the enactment of the Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act, signed into law by President Trump late yesterday. The law re-authorizes critical federal biodefense programs and agencies, including the BioShield Special Reserve Fund (SRF), the Biomedical Advanced Research and Development Authority (BARDA), and the Strategic National Stockpile (SNS). It authorizes funding for pandemic influenza product development and procurement for the first time.

BIO President and CEO Jim Greenwood issued the following statement:

“I applaud President Trump for signing this historic bi-partisan legislation. The PAHPAI Act provides critical flexibility and predictability for government agencies and their private sector partners by authorizing increased, multi-year funding for the BioShield Special Reserve Fund and by empowering BARDA to better address CBRN threat agents, pandemic influenza, emerging infectious diseases, and antimicrobial resistance. These investments in preparedness and medical countermeasure development will greatly enhance our ability to respond to potentially catastrophic attacks on the American public.”

FDA’s Atlanta lab relocating from Midtown to Fort Mac
Thursday, June 20, 2019 12:00 AM

The U.S. Food and Drug Administration (FDA) is relocating its Atlanta operations to Fort McPherson, a former Army base in southwest Atlanta.

The FDA, which is currently located on Peachtree Street in Midtown, will open a new lab and offices at Fort Mac, bringing 350 scientist and staff jobs to the project. 

That opens up a potentially big redevelopment opportunity in Midtown.

<< first < Prev 1 2 3 4 5 6 7 8 9 10 Next > last >>

Page 1 of 49